By Branwen Morgan For quite some time, the idea of a multinational funding scheme to support analysis in the Asia-Pacific area has been brewing. Finally, at the biannual Australian Health and Medical Research Congress late this past year, policymakers publicly talked about the merits and issues of such a venture for the first time. The congress in Melbourne, convened by the Australian Society for Medical Research , attracted about 1,500 delegates from 18 countries. Dignitaries at the November event included Australia’s minister for mental health and aging and the acting consul-general of Japan. .Combinations of lower dosages of BCX4208 with allopurinol showed synergistic results in sUA reduction. These doses of BCX4208 only and in conjunction with allopurinol were generally secure and well-tolerated. In keeping with prior BCX4208 clinical research, reductions in peripheral bloodstream lymphocytes were seen in individuals treated with BCX4208. The process included stopping guidelines for CD4+ cell counts below certain thresholds; zero subjects were discontinued because of this good reason. This successful research demonstrates that BCX4208 and allopurinol in mixture may synergistically reduce the crystals levels in the bloodstream and supports its continuing evaluation as a potential treatment for sufferers with gout, stated Dr.